We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · March 01, 2021

Safe Omission of Cardiac Monitoring in Select Patients With HER2+ MBC During Long-Term Trastuzumab Use

Breast Cancer Research and Treatment

 

Additional Info

Breast Cancer Research and Treatment
Cardiotoxicity During Long-Term Trastuzumab Use in Patients With HER2-Positive Metastatic Breast Cancer: Who Needs Cardiac Monitoring?
Breast Cancer Res Treat 2021 Jan 04;[EPub Ahead of Print], NI Bouwer, TG Steenbruggen, J van Rosmalen, HN Rier, JJEM Kitzen, ML van Bekkum, AJT Tije, PC de Jong, JC Drooger, C Holterhues, CH Smorenburg, MJM Kofflard, E Boersma, GS Sonke, MD Levin, A Jager

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading